Close
Almac
Achema middle east

Vetter Earns Frost & Sullivan’s Customer Value Award for the Third Time

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has been awarded the Frost & Sullivan’s 2023 Global Customer Value Leadership Award in the aseptic fill-and-finish market for the company’s high performance for its customers. The award, presented annually by the international growth strategy consulting firm, focuses on both business and customer impact along with industry status and trends in the market. In previous years the CDMO was awarded for their Customer Value Leadership and for their Customer Service Leadership.

Frost & Sullivan recognizes the companies that offer products or services customers find superior for the overall price, performance, and quality. The firm applies a rigorous analytical process to evaluate multiple nominees for each award category before determining the final recipient. The process involves a detailed evaluation of best practices criteria across the two dimensions – business and customer – for each nominated company.

Vetter’s core service offerings include drug product development, clinical and commercial aseptic filling, device assembly and secondary packaging. The award details Vetter’s consistent and successful efforts to put the customer at the center of its operations.

In response to the announcement, Frost & Sullivan’s Senior Industry Analyst Surbhi Gupta said, “Vetter offers highly specialized, state-of-the-art parenteral development and manufacturing expertise for the entire life cycle, from clinical development to commercial production and packaging. Through unwavering dedication to delivering the highest quality products and services and their exceptional knowledge and expertise, they strive to ensure their customers receive the best possible services.”

Additionally, Frost & Sullivan’s Best Practices Research Analyst Pavel Zhebrouski remarked, “In 2021, we recognized Vetter for its business and customer impact, and we remain impressed with the continuous innovation and sustained leadership. Vetter uniquely leverages its expertise to meet its customers’ needs, particularly the growing transition to injectables.”

Vetter Managing Director Peter Soelkner was proud of the industry recognition: “We always make our best efforts to provide customers with qualities that are highlighted in this prestigious award. We leverage our seven decades of experience and over 6,000 employees to do so.”

Managing Director fellow Thomas Otto emphasized: “We graciously acknowledge that this award shows we are on the right path, and we are looking to continue this approach towards the future.”

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »